{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:50:34Z","timestamp":1761821434858},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.2169\/internalmedicine.1592-18","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:04:08Z","timestamp":1555452248000},"page":"2231-2234","source":"Crossref","is-referenced-by-count":7,"title":["Long-term Effects of Androgen Deprivation in a Patient with Spinal and Bulbar Muscular Atrophy - A Case Report with 14 Years of Follow-up"],"prefix":"10.2169","volume":"58","author":[{"given":"Yasuhiro","family":"Hijikata","sequence":"first","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hashizume","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Banno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"},{"name":"Innovation Center for Clinical Research, National Center for Geriatrics and Gerontology, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[{"name":"Research Division of Dementia and Neurodegenerative Disease, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18: 671-680, 1968.","DOI":"10.1212\/WNL.18.7.671"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112: 209-232, 1989.","DOI":"10.1093\/brain\/112.1.209"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fischbeck KH. Kennedy disease. J Inherit Metab Dis 20: 152-158, 1997.","DOI":"10.1023\/A:1005344403603"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352: 77-79, 1991.","DOI":"10.1038\/352077a0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Katsuno M, Tanaka F, Adachi H, et al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99: 246-256, 2012.","DOI":"10.1016\/j.pneurobio.2012.05.007"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Banno H, Katsuno M, Suzuki K, et al. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65: 140-150, 2009.","DOI":"10.1002\/ana.21540"},{"key":"7","unstructured":"7. Katsuno M, Banno H, Suzuki K, et al.; Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9: 875-884, 2010."},{"key":"8","unstructured":"8. Hashizume A, Katsuno M, Suzuki K, et al. Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study. J Neurol Neurosurg Psychiatry 88: 1026-1032, 2017."},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378: 403-406, 1995.","DOI":"10.1038\/378403a0"},{"key":"10","unstructured":"10. van der Sluis TM, Bui HN, Meuleman EJ, et al. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol 187: 1601-1606, 2012."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hashizume A, Katsuno M, Banno H, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain 135: 2838-2848, 2012.","DOI":"10.1093\/brain\/aws170"},{"key":"12","unstructured":"12. Hashizume A, Katsuno M, Suzuki K, et al. A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord 25: 554-562, 2015."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sethi R, Sanfilippo N. Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer. Clin Interv Aging 4: 259-267, 2009.","DOI":"10.2147\/CIA.S4885"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154-164, 2005.","DOI":"10.1056\/NEJMoa041943"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181: 1998-2006, 2009.","DOI":"10.1016\/j.juro.2009.01.047"},{"key":"16","unstructured":"16. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28: 3448-3456, 2010."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hershman DL, Unger JM, Wright JD, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol 2: 453-461, 2016.","DOI":"10.1001\/jamaoncol.2015.4655"},{"key":"18","unstructured":"18. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol 14: 926-944, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/15\/58_1592-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T03:43:31Z","timestamp":1564803811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/15\/58_1592-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1592-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]}}}